Stevanato Group S.p.A. (NYSE:STVN) Shares Purchased by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC boosted its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 5.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,082,996 shares of the company’s stock after purchasing an additional 407,086 shares during the quarter. Stevanato Group makes up 2.3% of Conestoga Capital Advisors LLC’s holdings, making the stock its 16th largest position. Conestoga Capital Advisors LLC owned about 2.67% of Stevanato Group worth $176,128,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in STVN. Squarepoint Ops LLC raised its position in shares of Stevanato Group by 65.6% during the 2nd quarter. Squarepoint Ops LLC now owns 17,302 shares of the company’s stock worth $317,000 after purchasing an additional 6,853 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Stevanato Group by 222.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 251,606 shares of the company’s stock worth $4,614,000 after buying an additional 173,546 shares in the last quarter. Truist Financial Corp raised its holdings in shares of Stevanato Group by 47.0% during the second quarter. Truist Financial Corp now owns 26,034 shares of the company’s stock valued at $477,000 after acquiring an additional 8,321 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Stevanato Group in the third quarter valued at approximately $263,000. Finally, nVerses Capital LLC purchased a new position in shares of Stevanato Group in the third quarter valued at approximately $84,000.

Analyst Ratings Changes

Several research analysts recently commented on the company. Morgan Stanley reissued an “equal weight” rating and issued a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Bank of America upped their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Finally, Wolfe Research initiated coverage on Stevanato Group in a report on Friday, December 13th. They set an “outperform” rating and a $28.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Stevanato Group currently has an average rating of “Moderate Buy” and an average target price of €28.60 ($29.18).

Stevanato Group Price Performance

Shares of STVN stock opened at €22.59 ($23.05) on Monday. The firm’s 50-day moving average is €21.73 and its two-hundred day moving average is €20.50. Stevanato Group S.p.A. has a 12 month low of €16.56 ($16.90) and a 12 month high of €34.73 ($35.44). The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The company has a market capitalization of $6.84 billion, a PE ratio of 48.06, a price-to-earnings-growth ratio of 7.76 and a beta of 0.56.

Stevanato Group (NYSE:STVN) last posted its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.12) EPS for the quarter, missing analysts’ consensus estimates of €0.13 ($0.13) by (€0.01) (($0.01)). The business had revenue of €277.90 million during the quarter, compared to analysts’ expectations of €274.36 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Stevanato Group’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.16 EPS. Analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.